drugset / Trial / NCT00004199

Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

NCT00004199

Phase 3 Completed Pfizer
RandomizedTreatment

Summary

RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus cisplatin and gemcitabine in treating patients who have metastatic or recurrent non-small cell lung cancer.

Timeline

Start
1999-03
Primary completion
2001-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject prinomastat Small molecule Oral
Background Cisplatin Other / unclassified Intravenous
Background Gemcitabine Small molecule Intravenous

Indications